Jupiter Neurosciences raises about $2.0 million in registered direct offering to address Nasdaq equity rule
Jupiter Neurosciences sold 307,692 shares at $6.50 each in a registered direct offering that closed August 24, 2026, for gross proceeds of about $2.0 million before fees and expenses. The company believes the sale brings its stockholders' equity above the $2.5 million Nasdaq continued-listing requirement, but it is still waiting for Nasdaq's formal confirmation, and its shares may face delisting if compliance is not shown at its next periodic report.
Key points
- Shares issued: 307,692 common shares at $6.50 each, under an agreement dated August 21, 2026
- Gross proceeds: approximately $2.0 million before placement agent fees and offering expenses, closed August 24, 2026
- Nasdaq stockholders' equity requirement: $2.5 million; company awaiting formal determination of compliance
- Delisting risk remains if compliance is not evidenced at the next periodic report
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.